10 August 2022
Latham & Watkins Advises on Global Blood Therapeutics’ US$5.4 Billion Sale to Pfizer
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Charles Ruck Lead | Latham & Watkins LLP | Partner | Not stated | Orange Country |
| Robert Katz Lead | Latham & Watkins LLP | Partner | Not stated | New York |
| Daniel Rees Lead | Latham & Watkins LLP | Partner | Not stated | Orange Country |
| Taylor Ashton | Latham & Watkins LLP | Associate | Not stated | Orange Country |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 5.40bn (US$5.4 Billion)
- What the figure measures
- Total transaction value
- Client
- Not stated
- Counterparties
- Pfizer Inc. (Buy-side)
Global Blood Therapeutics, Inc. (Sell-side)